IL255632D0 - Solid dosage forms of palbociclib - Google Patents

Solid dosage forms of palbociclib

Info

Publication number
IL255632D0
IL255632D0 IL255632A IL25563217A IL255632D0 IL 255632 D0 IL255632 D0 IL 255632D0 IL 255632 A IL255632 A IL 255632A IL 25563217 A IL25563217 A IL 25563217A IL 255632 D0 IL255632 D0 IL 255632D0
Authority
IL
Israel
Prior art keywords
palbociclib
dosage forms
solid dosage
solid
forms
Prior art date
Application number
IL255632A
Other languages
Hebrew (he)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201562171177P priority Critical
Priority to US201662332973P priority
Priority to PCT/IB2016/053040 priority patent/WO2016193860A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of IL255632D0 publication Critical patent/IL255632D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56092955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL255632(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
IL255632A 2015-06-04 2017-11-13 Solid dosage forms of palbociclib IL255632D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201562171177P true 2015-06-04 2015-06-04
US201662332973P true 2016-05-06 2016-05-06
PCT/IB2016/053040 WO2016193860A1 (en) 2015-06-04 2016-05-24 Solid dosage forms of palbociclib

Publications (1)

Publication Number Publication Date
IL255632D0 true IL255632D0 (en) 2018-01-31

Family

ID=56092955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255632A IL255632D0 (en) 2015-06-04 2017-11-13 Solid dosage forms of palbociclib

Country Status (19)

Country Link
US (1) US20180207100A1 (en)
EP (1) EP3302565B1 (en)
JP (1) JP2017002034A (en)
CN (1) CN107666914A (en)
AU (2) AU2016272881C1 (en)
BR (1) BR112017025398A2 (en)
CA (1) CA2931892A1 (en)
CL (1) CL2017003089A1 (en)
CO (1) CO2017012362A2 (en)
CR (1) CR20170540A (en)
DK (1) DK3302565T3 (en)
DO (1) DOP2017000280A (en)
IL (1) IL255632D0 (en)
LT (1) LT3302565T (en)
MX (1) MX2017015579A (en)
PE (1) PE20180395A1 (en)
RU (1) RU2686840C1 (en)
TW (2) TWI635863B (en)
WO (1) WO2016193860A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105616418A (en) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 Pharmaceutical preparation containing cyclin inhibitor, and preparation method thereof
WO2017115315A1 (en) * 2015-12-30 2017-07-06 Dr. Reddy's Laboratories Limited Solid forms of palbociclib
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
CN110573183A (en) * 2017-04-21 2019-12-13 上海方楠生物科技有限公司 Pabocillin composition and preparation method thereof
CN106970177B (en) * 2017-06-06 2018-05-15 北京元延医药科技股份有限公司 The analyzing detecting method of Pa Boxini intermediates and its impurity
WO2019020715A1 (en) * 2017-07-28 2019-01-31 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2019056163A1 (en) * 2017-09-19 2019-03-28 浙江华海药业股份有限公司 N-formyl palbociclib and preparation method therefor and use thereof, and palbociclib preparation and quality control method therefor
WO2019166928A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
WO2019220253A1 (en) 2018-05-14 2019-11-21 Pfizer Inc. Oral solution formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
AT314370T (en) 2002-01-22 2006-01-15 Warner Lambert Co 2- (pyridin-2-ylamino) -pyrido (2,3-d) pyrimidin-7-one
PT1648889E (en) 2003-07-11 2008-12-10 Warner Lambert Co Isethionate salt of a selective cdk4 inhibitor
RU2009108006A (en) 2006-09-08 2010-10-20 Пфайзер Продактс Инк. (Us) Synthesis of 2- (pyridin-2-ilamino) -pyrido [2, 3-d] pyrimidin-7-ones
BR112012031516A2 (en) * 2010-06-09 2016-11-08 Abbott Lab solid dispersions containing kinase inhibitors
SI2958916T1 (en) 2013-02-21 2018-11-30 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
EP3033086A1 (en) * 2013-08-14 2016-06-22 Novartis AG Combination therapy for the treatment of cancer
AU2014348657A1 (en) * 2013-11-13 2016-05-19 Novartis Ag mTOR inhibitors for enhancing the immune response

Also Published As

Publication number Publication date
KR20180015232A (en) 2018-02-12
MX2017015579A (en) 2018-03-27
AU2019204689A1 (en) 2019-07-18
TW201711687A (en) 2017-04-01
CO2017012362A2 (en) 2018-03-28
TW201906611A (en) 2019-02-16
LT3302565T (en) 2019-12-27
CR20170540A (en) 2018-02-02
EP3302565B1 (en) 2019-11-06
JP2017002034A (en) 2017-01-05
AU2016272881A1 (en) 2017-12-07
DK3302565T3 (en) 2020-01-02
DOP2017000280A (en) 2018-01-15
EP3302565A1 (en) 2018-04-11
US20180207100A1 (en) 2018-07-26
AU2016272881B2 (en) 2019-04-11
RU2686840C1 (en) 2019-05-06
BR112017025398A2 (en) 2018-08-07
PE20180395A1 (en) 2018-02-28
CA2931892A1 (en) 2016-12-04
CL2017003089A1 (en) 2018-05-11
AU2016272881C1 (en) 2019-10-03
TWI635863B (en) 2018-09-21
CN107666914A (en) 2018-02-06
WO2016193860A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
SG11201606080SA (en) Dihydropyrrolopyridine inhibitors of ror-gamma
DK3310231T3 (en) Dosage decor
IL257026D0 (en) Solid state forms of eluxadoline
PL3207043T3 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
GB201618482D0 (en) Pharmaceutical compositions
GB201409471D0 (en) Pharmaceutical composition
HK1232137A1 (en) Therapeutic compounds and compositions
DK3302565T3 (en) Fixed dosage forms of palbociclib
GB201415569D0 (en) Therapeutic Compounds
IL254030D0 (en) שימוש בפרידופידין לשיפור תפקוד קוגניטיבי ולטיפול במחלת אלצהיימר
IL259560D0 (en) Inhibitors of the menin-mll interaction
GB201404922D0 (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
SG11201609810YA (en) Solid forms of an antiviral compound
EP3182975A4 (en) High dosage strength tablets of rucaparib
GB201409485D0 (en) Pharmaceutical composition
IL255194D0 (en) Solid forms
SI3154526T1 (en) Solid state forms of sofosbuvir
CZ2016196A3 (en) Solid forms of Ibrutinib
IL246613D0 (en) Dosage regimen of ferric trimaltol
GB201409488D0 (en) Pharmaceutical composition
GB201514754D0 (en) Compounds
GB201514751D0 (en) Compounds
GB201419579D0 (en) Pharmaceutical compound
GB201506658D0 (en) Pharmaceutical compounds